9 results
Primary objective: To study the influence of repeated oral administration of ketoconazole, a potent CYP3A4 inhibitor, in a therapeutic dose on the plasma pharmacokinetics (PK) of eribulin administered via intravenous (IV) infusion.Secondary…
The primary objective of this study is to determine the excretion balance and to elucidate the metabolic pathway of eribulin in vivo after a single dose of carbon-14 radio-labeled eribulin (14C-eribulin), inpatients with advanced solid tumors.
Primary objective• To assess the effect of cytochrome P450 3A4 enzyme (CYP3A4) induction by rifampicin on the pharmacokinetics (PK) of eribulin following intravenous (IV) administrationSecondary objectives• To assess the safety of eribulin when co-…
To study the influence of hepatic impairment on plasma pharmacokinetic parameters of eribulin mesylate (E7389) following an IV administration.
Primary objectives:• To evaluate the safety and tolerability of BMS-914143 as measured by the frequency of SAEs and discontinuations due to AEs;• To assess the HBeAg seroconversion rate at 24 weeks off treatment (Week 72).Secondary objective• To…
PrimairyTo assess whether bevacizumab-800CW allows for intraoperative fluorescence imaging of perihilar cholangiocarcinoma and what dose provides the best visualization of tumor tissue by determining the tumor-to-background (TBR) ratio ex…
Part 11. Determine if accumulation of the fluorescent tracer bevacizumab-800CW can be detected for identification of soft tissue sarcoma during surgery.2. Identify two doses of bevacizumab-800CW that provide the best visualization of tumour tissue…
Part 1 1. Determine if accumulation of the fluorescent tracer bevacizumab-800CW can be detected for identification of pancreatic cancer tissue during surgery.2. Identify two doses of conjugate that provide the best visualization of tumor tissue…
Dual Primary objective: - To demonstrate the superiority of Dato-DXd compared to ICC by assessment of PFS in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer, who have been treated with 1 or 2 lines of chemotherapy…